| pubmed-article:3549120 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0001175 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0007806 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0445223 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0185125 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0280039 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C1552599 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C1704787 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:3549120 | lifeskim:mentions | umls-concept:C0449435 | lld:lifeskim |
| pubmed-article:3549120 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:3549120 | pubmed:dateCreated | 1987-5-8 | lld:pubmed |
| pubmed-article:3549120 | pubmed:abstractText | We investigated the clinical pharmacokinetics of azidothymidine (N3TdR) as part of a phase I/II trial in the treatment of acquired immunodeficiency syndrome and related diseases. During the 6-week course of therapy, drug levels in plasma, cerebrospinal fluid, and urine were determined by HLPC. The plasma half-life of N3TdR was 1.1 hour. The total body clearance was 1.3 L/kg/hr. At intravenous doses of 5 mg/kg or oral doses of 10 mg/kg, plasma levels were continuously maintained above the target level of 1 mumol/L. Oral bioavailability was 63% +/- 13%. Substantial penetration of N3TdR into cerebrospinal fluid was demonstrated. At doses of 5 mg/kg intravenously or 10 mg/kg orally, cerebrospinal fluid drug levels exceeded and were maintained close to 1 mumol/L. Nineteen percent of the administered dose was excreted unchanged into the urine. Renal clearance was 0.23 L/kg/hr. N3TdR possesses pharmacokinetic properties that would facilitate the long-term treatment of patients with acquired immunodeficiency syndrome: it can be given orally and it penetrates the central nervous system. | lld:pubmed |
| pubmed-article:3549120 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3549120 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3549120 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3549120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3549120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3549120 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3549120 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:3549120 | pubmed:issn | 0009-9236 | lld:pubmed |
| pubmed-article:3549120 | pubmed:author | pubmed-author:CollinsJ MJM | lld:pubmed |
| pubmed-article:3549120 | pubmed:author | pubmed-author:MyersC ECE | lld:pubmed |
| pubmed-article:3549120 | pubmed:author | pubmed-author:ThomasRR | lld:pubmed |
| pubmed-article:3549120 | pubmed:author | pubmed-author:BroderSS | lld:pubmed |
| pubmed-article:3549120 | pubmed:author | pubmed-author:YarchoanRR | lld:pubmed |
| pubmed-article:3549120 | pubmed:author | pubmed-author:JenkinsJ FJF | lld:pubmed |
| pubmed-article:3549120 | pubmed:author | pubmed-author:KleckerR... | lld:pubmed |
| pubmed-article:3549120 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3549120 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:3549120 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3549120 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3549120 | pubmed:pagination | 407-12 | lld:pubmed |
| pubmed-article:3549120 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:meshHeading | pubmed-meshheading:3549120-... | lld:pubmed |
| pubmed-article:3549120 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3549120 | pubmed:articleTitle | Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. | lld:pubmed |
| pubmed-article:3549120 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3549120 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3549120 | lld:pubmed |
